Phase 3 study finds once ‐daily valbenazine improves symptoms of tardive dyskinesia

Once‐daily dosing of the vesicular monoamine transporter 2 (VMAT2) inhibitor valbenazine resulted in significant improvement over placebo in patients with tardive dyskinesia (TD) and an underlying psychotic or mood disorder, a Phase 3 trial has found. Soon after the study's publication online March 21 in the American Journal of Psychiatry, the Food and Drug Administration approved valbenazine as the first available treatment for TD (see From the FDA, page 8).
Source: The Brown University Psychopharmacology Update - Category: Psychiatry Tags: Adverse Events Source Type: research